Search U.S. Product Recalls Database

Showing 241–260 of 14362 results

Sort:

Sucralfate Tablets (Amerisource) – Quality Monitoring Failure (2025)

CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.

Class IIModerate

FDAJul 29, 2025Nationwide• Amerisource Health Services LLC

Anabolic Research WINN-50 (Dynamic Sports) – sub-potent supplement (2025)

Dietary supplement involved degradation of an ingredient. Product is sub-potent for Vitamin B12 not meeting label claims.

Class IIILow

FDA

Stay Informed

Search Product Recalls

Sucralfate Tablets (Amerisource) – Quality Monitoring Failure (2025)

Anabolic Research WINN-50 (Dynamic Sports) – sub-potent supplement (2025)

Duloxetine Capsules (Breckenridge) – Nitrosamine Impurity (2025)

Doxepin Hydrochloride Capsules (Alembic) – Nitrosamine Impurity (2025)

Whole Grain Jalapeno Bagel (Bonami Baking) – undeclared milk (2025)

Wheat Hamburger Buns (Bonami Baking) – Undeclared Allergens (2025)

Whole Wheat Chocolate Croissants (Bonami Baking) – undeclared milk soy (2025)

Lorazepam Injection (Hikma) – Compound Impurities (2025)

Quick Touch Alcohol Prep Pads (Yangzhou Yulou) – Manufacturing Deviation (2025)

Belsomra Tablets (Merck) – Dissolution Performance (2025)

Amlodipine Olmesartan Tablets (Ascend) – Dissolution Failure (2025)

DermaKleen Antiseptic Soap (DermaRite Industries) – Microbial Contamination (2025)

DermaSarra Analgesic (DermaRite Industries) – Microbial Contamination (2025)

Duloxetine Capsules (Breckenridge Pharmaceutical) – Impurity Concern (2025)

Clover Valley Whole Milk (Dollar General) – temperature abuse (2025)

Sucralfate Tablets (Nostrum Laboratories) – Quality Program Disruption (2025)

Bicillin L-A Injection (Pfizer) – Particulate Inspection Problem (2025)

Bicillin L-A Injection (Pfizer) – Particulate Inspection Problem (2025)

Tropicamide Ophthalmic Solution (Imprimis NJOF) – Potency Concern (2025)

Rizatriptan Tablets (Ascend Laboratories) – Impurity Detection (2025)